Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Technical Analysts See Bullish Signs for Biotech ETFs

6/06/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzkvmdivndi2l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

After a sharp sell-off in March and languish trading through May, the biotechnology sector and related exchange traded funds are looking to break out.

The iShares Nasdaq Biotechnology ETF, which tracks biotech and pharma stocks on the Nasdaq, fell 9.6% over the past three months, but the ETF is up 1.6% over the past week and 6.3% higher over the last month. Last week, IBB broke above its 50-day moving average.

Ed Ponsi, managing direction of Barchetta Capital Mangement, pointed out that IBB’s break above its short-term resistance level, the first time since March, was a bullish indicator, reports Lee Brodie for CNBC.

Furthermore, Ponsi noted that IBB broke out of a symmetrical triangle pattern that has formed for weeks. The symmetrical triangle pattern is recognized by its distinct triangle shape formed by two converging trendlines that connect recent peaks and troughs.

IBB’s symmetrical triangle pattern showed its trendlines converged around $231 per share – IBB currently trades around $245 per share. The two trendlines act as barriers on prices increases and decreases, but when the price breaches one of these lines, a sharp move typically follows. Currently, the ETF is breaking out on the bullish side.

Looking at individual picks, Ponsi argued that biotech firms like Celgene and big pharma Regeneron are also showing bullish chart patterns.

“That would mean the monster sell-off has created some terrific buying opportunities,” Mad Money’s Cramer noted in the article. “I think Ponsi is dead right.”

This article has been extracted from http://www.etftrends.com, please click on this link to read the article in full http://www.etftrends.com/2014/06/technical-analysts-see-bullish-signs-for-biotech-etfs/

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdyvmtkvmtavndkvmtavntuvc2h1dhrlcnn0b2nrxzqymzk2mjg2ni5qcgcixsxbinailcj0ahvtyiisijm4mhgxmdajil1d

Long Term Transition, Not Long Term Tradition...

2017-06-20 09:00:00 +0100

It seems odd that while 88% of businesses are undergoing some kind of digital transformation[1], only 25%[2] of them have a clear understanding of their digital transformation journey. So what's driving so many businesses to pursue digital with such recklessness? Broadly speaking, the reason is simply the unprecedented rate of change in digital solutions and services. As we ride the digital tidal wave, consumers and employees change their expectations, ...

W1siziisijiwmtcvmdyvmtmvmtavmjqvmjuvodcxl3nodxr0zxjzdg9ja181njewnja3mzmuanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

How Great Leaders Cultivate Great Teams

2017-06-13 12:00:00 +0100

There's a difference between being a boss and being a leader. Leaders know how to inspire the best from their teams to achieve industry-leading results. For our latest blog, we spoke to our Managing Director, Roy Dungworth, to discover how businesses can create a culture that inspires great people to do great things together. Success in business doesn't begin and end with great leadership. Great leaders inspire their teams to want to do more and be bett...